Redox-Cycling "Mitocans" as Effective New Developments in Anticancer Therapy

Area of Science:

• Biochemistry
• Pharmacology
• Mitochondrial Biology

Background:

• Cancer cells exhibit altered metabolism and redox balance.
• Mitochondria are key targets for cancer therapy due to their central role in energy production and redox homeostasis.
• Existing cancer therapies often cause significant side effects due to lack of specificity.

Purpose of the Study:

• To investigate the potential of redox-cycling quinone/ascorbate (Q/A) pairs as targeted anticancer agents.
• To evaluate the efficacy and safety of Q/A redox-pairs in vitro and in vivo.
• To elucidate the mechanisms underlying the selective toxicity of Q/A pairs towards cancer cells.

Main Methods:

• Screening of eleven Q/A redox-pairs in cultured cancer cells and tumor-bearing mice.
• Assessment of cell proliferation, viability, mitochondrial superoxide production, ATP levels, and tissue redox state.
• Analysis of tumor-associated NADH oxidase (tNOX) expression, tumor growth, and animal survival.

Main Results:

• Unprenylated Q/A redox-pairs demonstrated potent dose-dependent antiproliferative and cytotoxic effects on cancer cells.
• Cancer cells treated with Q/A pairs showed increased mitochondrial superoxide and rapid ATP depletion.
• Normal cells exhibited preserved viability and energy homeostasis, with only mild, well-tolerated mitochondrial oxidative stress.
• Benzoquinone/ascorbate pairs were more effective than naphthoquinone/ascorbate, with coenzyme Q0/ascorbate showing the strongest anticancer activity.
• Mechanisms include cancer-specific downregulation of quinone prenylation, accelerated Q/A redox-cycling in impaired cancer mitochondria, and tNOX downregulation.

Conclusions:

• Redox-cycling Q/A pairs, particularly unprenylated forms like coenzyme Q0/ascorbate, represent a targeted pharmacological strategy against cancer.
• The selective toxicity is driven by the redox imbalance in cancer cell mitochondria, leading to amplified oxidative stress and energy crisis.
• This approach offers a promising therapeutic window with minimal adverse effects on normal cells and tissues.